Molecular mimicry and antigen-specific T cell responses in multiple sclerosis and chronic CNS lyme disease

Journal of Autoimmunity

Volumn 16, Issue 3, 2001, Pages 187-192

  Martin, Roland ^a   Gran, Bruno ^a   Zhao, Yingdong ^b   Markovic Plese, Silva ^a   Bielekova, Bibiana ^a   Marques, Adriana ^c   Sung, Myong Hee ^b   Hemmer, Bernhard ^a,e   Simon, Richard ^b   McFarland, Henry F ^d   Pinilla, Clemencia ^d  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

^e PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Autoimmunity; Molecular mimicry; Multiple sclerosis; T cell recognition

Indexed keywords

ALTERED PEPTIDE LIGAND; AUTOANTIGEN; CGP 77116; EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN; MYELIN; MYELIN BASIC PROTEIN; PEPTIDE LIBRARY; SYNTHETIC PEPTIDE; T LYMPHOCYTE RECEPTOR; TIPLIMOTIDE; UNCLASSIFIED DRUG;

ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; CENTRAL NERVOUS SYSTEM INFECTION; CHRONIC DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CROSS REACTION; DISEASE EXACERBATION; DRUG HYPERSENSITIVITY; HUMAN; HUMAN CELL; IMMUNOPATHOGENESIS; LYME DISEASE; MOLECULAR MIMICRY; MULTICENTER STUDY; MULTIPLE SCLEROSIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN MOTIF; SEQUENCE HOMOLOGY; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE RECEPTOR GENE;

EID: 0034979369     PISSN: 08968411     EISSN: None     Source Type: Journal    
DOI: 10.1006/jaut.2000.0501     Document Type: Conference Paper

References (48)

1. Immunological aspects of demyelinating diseases
2. Axonal transection in the lesions of multiple sclerosis
3. Multiple sclerosis
4. On the immunopathology of plaque development and repair in multiple sclerosis
5. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination
6. Escape from "horror autotoxicus": Pathogenesis and treatment of autoimmune disease
7. Animal models
8. The T lymphocyte in experimental allergic encephalomyelitis
9. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatibility complex
10. A full genome search in multiple sclerosis
11. Patients with multiple sclerosis carry DQB1 genes which encode shared polymorphic aminoacid sequences
12. A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22
13. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand
14. Clinical viral infections and multiple sclerosis
15. Chickenpox and multiple sclerosis: A case report
16. Amino Acid homology between the encephalitogenic site of myelin basic protein and virus: Mechanism for autoimmunity
17. Virus-induced autoimmune demyelinating disease of the central nervous system. Chapter 24
18. Molecular mimicry in T cell-mediated autoimmunity: Viral peptides activate human T cell clones specific for myelin basic protein
19. ζ phosphorylation without ZAP-70 activation induced by TCR antagonists or partial agonists
20. Tickling the TCR: Selective T-cell functions stimulated by altered peptide ligands
21. Essential flexibility in the T cell recognition of antigen
22. Identification of high potency microbial and self ligands for a human autoreactive class II-restricted T cell clone
23. Modifications of peptide ligands enhancing T cell responsiveness imply large numbers of stimulatory ligands for autoreactive T cells
24. T cell receptor antigen recognition based on peptide scans leads to the identification of agonist ligands with no sequence homology
25. Identification of candidate epitopes and molecular mimics in chronic Lyme disease
26. Probing degeneracy in T-cell recognition using combinatorial peptide libraries
27. Exploring immunological specificity using synthetic peptide combinatorial libraries
28. Contribution of individual amino acids within MHC molecule or antigenic peptide to TCR ligand potency
29. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices
30. Molecular mimicry by herpes simplex virus-type 1: Autoimmune disease after viral infection
31. In vivo survival of viral antigen-specific T cells that induce experimental autoimmune encephalomyelitis
32. Measles encephalomyelitis: Clinical and immunological studies
33. Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand
34. Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor
35. Peptide-major histocompatibility complex class II complexes with mixed agonist/antagonist properties provide evidence for ligand-related differences in T cell receptor-dependent intracellular signaling
36. Partial T cell signaling: Altered phospho-ζ and lack of zap70 recruitment in APL-induced T cell anergy
37. Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon γ and tumor necrosis factor a production
38. Dynamics of autoimmune T cell infiltration: Reversal of paralysis and disappearance of inflammation following treatment of experimental encephalomyelitis with a myelin basic protein peptide analog
39. An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis
40. A T cell receptor antagonist peptide induces T cells that mediate bystander suppression and prevents experimental autoimmune encephalomyelitis induced by multiple myelin antigens
41. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells
42. Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 gag variants
43. Altered peptide ligands narrow the repertoire of cellular immune responses by interfering with T-cell priming
44. Evolution of the T-cell repertoire during the course of experimental immune-mediated demyelinating disease
45. Differential activation of human autoreactive T cell clones by altered peptide ligands derived from myelin basic protein peptide (87-99)
46. Human T-cell response to myelin basic protein peptide (83-99): Extensive heterogeneity in antigen recognition, function, and phenotype
47. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial
48. NBI-5788, an altered MBP 83-99 peptide, induces a T-helper 2-like immune response in multiple sclerosis patients